Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial

ConclusionEmpagliflozin improved cardiovascular death or heart failure hospitalization risk across the range of baseline health status. Empagliflozin improved health status across various domains, and this benefit was sustained during long-term follow-up.Clinical trial registrationURL:https://www.clinicaltrials.gov. Unique identifier: NCT03057977.
Source: European Heart Journal - Category: Cardiology Source Type: research